Threat or promise by 2020? The FT Global Pharmaceutical and Biotechnology Conference 2014
“Whether this landscape offers greater promise or threat depends on your point of view,” remarked Andrew Ward, the Financial Times’ pharmaceuticals correspondent who chaired the first day of the FT Global Pharmaceutical and Biotechnology Conference 2014. All eyes were on the landscape between now and 2020, and potential areas of growth, change and challenge across the biotech and pharma industries.
The new health economy
In the opening session, View from the Top: The Life Sciences Industry in the New Health Economy 2020, Bahija Jallal, executive vice president of AstraZeneca (LSE: AZN) and head of MedImmune, spoke of the privilege of being able to come to work every day for a noble cause.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze